{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:34:40Z","timestamp":1770528880228,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91129725,81572536"],"award-info":[{"award-number":["91129725,81572536"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["14140901700"],"award-info":[{"award-number":["14140901700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support","award":["20152215"],"award-info":[{"award-number":["20152215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12894-018-0416-6","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T03:54:52Z","timestamp":1543809292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors"],"prefix":"10.1186","volume":"18","author":[{"given":"Liancheng","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baijun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenfei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiming","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-4617","authenticated-orcid":false,"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"416_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893\u2013917.","journal-title":"Int J Cancer"},{"key":"416_CR2","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1464-410X.2005.05798.x","volume":"96","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005;96:985\u20139.","journal-title":"BJU Int"},{"key":"416_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"416_CR4","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.","journal-title":"N Engl J Med"},{"key":"416_CR5","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"416_CR6","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","volume":"32","author":"E Basch","year":"2014","unstructured":"Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436\u201348.","journal-title":"J Clin Oncol"},{"key":"416_CR7","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AH, A\u2019Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742\u20138.","journal-title":"J Clin Oncol"},{"key":"416_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","volume":"100","author":"JE Ang","year":"2009","unstructured":"Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100:671\u20135.","journal-title":"Br J Cancer"},{"key":"416_CR9","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563\u201371.","journal-title":"J Clin Oncol"},{"key":"416_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"416_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"416_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"416_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"416_CR14","doi-asserted-by":"publisher","first-page":"E583","DOI":"10.5489\/cuaj.1891","volume":"8","author":"R Clayton","year":"2014","unstructured":"Clayton R, Wu J, Heng DY, et al. A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. Can Urol Assoc J = Journal de l'Association des urologues du Canada. 2014;8:E583\u201390.","journal-title":"Can Urol Assoc J = Journal de l'Association des urologues du Canada"},{"key":"416_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12894-016-0132-z","volume":"16","author":"DM Poon","year":"2016","unstructured":"Poon DM, Chan K, Lee SH, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience. BMC Urol. 2016;16:12.","journal-title":"BMC Urol"},{"key":"416_CR16","first-page":"5615","volume":"35","author":"RS Davies","year":"2015","unstructured":"Davies RS, Smith C, Button MR, et al. What predicts minimal response to Abiraterone in metastatic castrate-resistant prostate Cancer? Anticancer Res. 2015;35:5615\u201321.","journal-title":"Anticancer Res"},{"key":"416_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group. J Clin Oncol. 2008;26:1148\u201359.","journal-title":"J Clin Oncol"},{"key":"416_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/iju.13051","volume":"23","author":"Y Sun","year":"2016","unstructured":"Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23:404\u201311.","journal-title":"Int J Urol"},{"key":"416_CR19","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Kheoh T, Yu MK, et al. Prior endocrine therapy impact on Abiraterone acetate clinical efficacy in metastatic castration-resistant prostate Cancer: post-hoc analysis of randomised phase 3 studies. Eur Urol. 2015.","DOI":"10.1016\/j.eururo.2015.10.021"},{"key":"416_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clgc.2011.06.006","volume":"9","author":"M Nakabayashi","year":"2011","unstructured":"Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011;9:95\u2013103.","journal-title":"Clin Genitourin Cancer"},{"key":"416_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.22085","volume":"107","author":"M Nakabayashi","year":"2006","unstructured":"Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer. 2006;107:975\u201381.","journal-title":"Cancer"},{"key":"416_CR22","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","volume":"51","author":"Y Loriot","year":"2015","unstructured":"Loriot Y, Eymard JC, Patrikidou A, et al. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. Eur J Cancer. 2015;51:1946\u201352.","journal-title":"Eur J Cancer"},{"key":"416_CR23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","volume":"50","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European expert consensus panel. Eur J Cancer. 2014;50:1617\u201327.","journal-title":"Eur J Cancer"},{"key":"416_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.2007.13.6804","volume":"26","author":"RW Ross","year":"2008","unstructured":"Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008;26:842\u20137.","journal-title":"J Clin Oncol"},{"key":"416_CR25","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.2010.31.2405","volume":"29","author":"M Yang","year":"2011","unstructured":"Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29:2565\u201373.","journal-title":"J Clin Oncol"},{"key":"416_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.eururo.2014.01.030","volume":"67","author":"AA Azad","year":"2015","unstructured":"Azad AA, Eigl BJ, Leibowitz-Amit R, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol. 2015;67:441\u20137.","journal-title":"Eur Urol"},{"key":"416_CR27","doi-asserted-by":"crossref","unstructured":"Liancheng Fan, Rui Wang, Chenfei Chi, Wen Cai, Yong Zhang, Hongyang Qian, Xiaoguang Shao, Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Lixin Zhou, Baijun Dong, Wei Xue. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. The Prostate. 2018;78(4):250-56.","DOI":"10.1002\/pros.23465"},{"key":"416_CR28","doi-asserted-by":"crossref","unstructured":"Baijun Dong, Liancheng Fan, Yanqing Wang, Chenfei Chi, Xiaowei Ma, Rui Wang, Wen Cai, Xiaoguang Shao, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Xiaonan Kang, Lixin Zhou, Wei Xue. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. The Prostate. 2017;77(13):1373-380.","DOI":"10.1002\/pros.23397"},{"key":"416_CR29","doi-asserted-by":"crossref","unstructured":"Liancheng Fan, Yanqing Wang, Chenfei Chi, Jiahua Pan, Shangguan Xun, Zhixiang Xin, Jianian Hu, Lixin Zhou, Baijun Dong, Wei Xue. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU International. 2017;120(2):226-32.","DOI":"10.1111\/bju.13781"},{"key":"416_CR30","doi-asserted-by":"crossref","unstructured":"Liancheng Fan, Xiao Wang, Chenfei Chi, Yanqing Wang, Wen Cai, Xiaoguang Shao, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Zhixiang Xin, Jianian Hu, Shaowei Xie, Rui Wang, Lixin Zhou, Baijun Dong, Wei Xue. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. The Prostate. 2017;77(12):1233-241.","DOI":"10.1002\/pros.23381"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0416-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-018-0416-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0416-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:10:10Z","timestamp":1575313810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-018-0416-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1186\/s12894-018-0416-6","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Approval for this study was obtained from the Committee for Ethics of Renji Hospital. Sixty patients with chemotherapy-naive mCRPC provided informed consent and were enrolled in our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"110"}}